{"id":12515,"date":"2021-05-17T10:22:33","date_gmt":"2021-05-17T09:22:33","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=11303"},"modified":"2021-10-11T14:50:45","modified_gmt":"2021-10-11T13:50:45","slug":"progress-for-amr-tests","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/progress-for-amr-tests\/","title":{"rendered":"Progress for AMR tests"},"content":{"rendered":"\n


 Article published in the Linksbridge Weekly News Roundup<\/a> on Wednesday 12 May 2021.<\/p>\n\n\n\n

Mentions: CARB-X, diagnostics, SpeeDx, chlamydia, gonorrhea, AMR, T2 Biosystems, BARDA, Qpex, drugs<\/em>
 
May 12, 2021 \u2014 Boston University-led CARB-X announced Monday that it will give Australian diagnostics specialist SpeeDx up to $1.8 million (plus up to $1.9 million in milestones) to develop a one-hour combination test for chlamydia and gonorrhea that also determines the susceptibility of gonorrhea infections to common antibiotics. SpeeDX plans to combine its test with a portable, battery-operated device from Britain\u2019s QuantuMDx, making the diagnostic ready for \u201cremote or low-resource settings around the world,\u201d the press release said.
 
Meanwhile, former CARB-X grant recipient T2 Biosystems announced last week that it has modified its existing contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to accelerate the development of several diagnostic panels to detect bloodborne antibiotic-resistant threats. Those panels include the Massachusetts company\u2019s T2Resistance\u2014the first test to graduate from CARB-X\u2019s portfolio into successful commercialization.
 
In other antimicrobial resistance news, another BARDA partner, San Diego-based Qpex Biopharma, announced Wednesday that it has dosed the first participant in a Phase 1 study of its ORAvance ultra-broad-spectrum oral beta-lactamase inhibitor (co-administered with beta-lactam antibiotics) against drug-resistant gram-negative bacterial infections.
 
MORE INFORMATION:
 
CARB-X press release<\/a>
T2 Biosystems press release<\/a>
First CARB-X diagnostic approved<\/a> (November 20, 2019)
Qpex press release<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

 Article published in the Linksbridge Weekly News Roundup on Wednesday 12 May 2021. Mentions: CARB-X, diagnostics, SpeeDx, chlamydia, gonorrhea, AMR, T2 Biosystems, BARDA, Qpex, drugs May 12, 2021 \u2014 Boston University-led CARB-X announced Monday that it will give Australian diagnostics specialist SpeeDx up to $1.8 million (plus up to $1.9 million in milestones) to develop a […]<\/p>\n","protected":false},"author":139,"featured_media":12325,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[31],"tags":[],"acf":[],"yoast_head":"\nProgress for AMR tests - Interface nationale ANTIBIOR\u00c9SISTANCE<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/progress-for-amr-tests\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Progress for AMR tests - Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/progress-for-amr-tests\/\" \/>\n<meta property=\"og:site_name\" content=\"Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-17T09:22:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-10-11T13:50:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Biologie-recherche.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"568\" \/>\n\t<meta property=\"og:image:height\" content=\"509\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/progress-for-amr-tests\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/progress-for-amr-tests\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"Progress for AMR tests\",\"datePublished\":\"2021-05-17T09:22:33+00:00\",\"dateModified\":\"2021-10-11T13:50:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/progress-for-amr-tests\/\"},\"wordCount\":228,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/progress-for-amr-tests\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Biologie-recherche.jpg\",\"articleSection\":[\"Actualit\u00e9s\"],\"inLanguage\":\"fr-FR\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/progress-for-amr-tests\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/progress-for-amr-tests\/\",\"name\":\"Progress for AMR tests - Interface nationale ANTIBIOR\u00c9SISTANCE\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/progress-for-amr-tests\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/progress-for-amr-tests\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Biologie-recherche.jpg\",\"datePublished\":\"2021-05-17T09:22:33+00:00\",\"dateModified\":\"2021-10-11T13:50:45+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/progress-for-amr-tests\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/progress-for-amr-tests\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/progress-for-amr-tests\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Biologie-recherche.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Biologie-recherche.jpg\",\"width\":568,\"height\":509,\"caption\":\"Cr\u00e9dit : Pixabay\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/progress-for-amr-tests\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Infos pratiques & communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Actualit\u00e9s\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Progress for AMR tests\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"name\":\"Interface nationale ANTIBIOR\u00c9SISTANCE\",\"description\":\"PPR Antibior\u00e9sistance - Inserm\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Progress for AMR tests - Interface nationale ANTIBIOR\u00c9SISTANCE","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/progress-for-amr-tests\/","og_locale":"fr_FR","og_type":"article","og_title":"Progress for AMR tests - Interface nationale ANTIBIOR\u00c9SISTANCE","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/progress-for-amr-tests\/","og_site_name":"Interface nationale ANTIBIOR\u00c9SISTANCE","article_published_time":"2021-05-17T09:22:33+00:00","article_modified_time":"2021-10-11T13:50:45+00:00","og_image":[{"width":568,"height":509,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Biologie-recherche.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"\u00c9milie Noguez","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/progress-for-amr-tests\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/progress-for-amr-tests\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"Progress for AMR tests","datePublished":"2021-05-17T09:22:33+00:00","dateModified":"2021-10-11T13:50:45+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/progress-for-amr-tests\/"},"wordCount":228,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/progress-for-amr-tests\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Biologie-recherche.jpg","articleSection":["Actualit\u00e9s"],"inLanguage":"fr-FR"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/progress-for-amr-tests\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/progress-for-amr-tests\/","name":"Progress for AMR tests - Interface nationale ANTIBIOR\u00c9SISTANCE","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/progress-for-amr-tests\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/progress-for-amr-tests\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Biologie-recherche.jpg","datePublished":"2021-05-17T09:22:33+00:00","dateModified":"2021-10-11T13:50:45+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/progress-for-amr-tests\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/progress-for-amr-tests\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/progress-for-amr-tests\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Biologie-recherche.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Biologie-recherche.jpg","width":568,"height":509,"caption":"Cr\u00e9dit : Pixabay"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/progress-for-amr-tests\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/"},{"@type":"ListItem","position":2,"name":"Infos pratiques & communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/"},{"@type":"ListItem","position":3,"name":"Actualit\u00e9s","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/"},{"@type":"ListItem","position":4,"name":"Progress for AMR tests"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","name":"Interface nationale ANTIBIOR\u00c9SISTANCE","description":"PPR Antibior\u00e9sistance - Inserm","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-29 21:42:59","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/12515"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/comments?post=12515"}],"version-history":[{"count":2,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/12515\/revisions"}],"predecessor-version":[{"id":17833,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/12515\/revisions\/17833"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media\/12325"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media?parent=12515"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/categories?post=12515"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/tags?post=12515"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}